You are here: Industry Insights > Keytruda

News List

FDA approves Merck's Keytruda in combination with Inlyta biospectrumasia
April 23, 2019
Merck has announced that the U.S. Food and Drug Administration has approved KEYTRUDA, Merck’s anti-PD-1 therapy……
China’s NMPA approves Novartis’ Cosentyx and Merck’s Keytruda pharmaceutical-technology
April 23, 2019
Novartis has announced that the Chinese National Medical Product Administration (NMPA) has approved its plaque psoriasis drug Cosentyx (secukinumab).
Merck heaps early pressure on Bristol-Myers' Opdivo with Keytruda's kidney cancer debut fiercepharma
April 23, 2019
Bristol-Myers Squibb investors knew trouble would come for Opdivo when Merck’s Keytruda entered the kidney cancer arena, but that trouble just arrived two months early.
FDA Approves Expanded Monotherapy Label for Merck’s Keytruda (pembrolizumab) for First-Line Treatment of NSCLC drugs
April 18, 2019
FDA Approves Expanded Monotherapy Label for Merck’s Keytruda (pembrolizumab) for First-Line Treatment of NSCLC.
Keytruda continues its lung cancer land grab with another FDA nod fiercepharma
April 15, 2019
Solo therapy with Merck & Co.’s Keytruda is already approved in previously untreated non-small cell lung cancer patients with high levels of the PD-L1 biomarker.
FDA expands first-line NSCLC label for Merck & Co.'s Keytruda firstwordpharma
April 12, 2019
FDA expands first-line NSCLC label for Merck & Co.'s Keytruda.
Keytruda spurs long responses in small cell lung cancer fiercepharma
April 10, 2019
ATLANTA—Merck & Co. is awaiting an FDA decision for Keytruda in previously treated small cell lung cancer, and it has new numbers to boost its case.
Merck’s KEYTRUDA receives approval in China biospectrumasia
April 02, 2019
Merck, known as MSD outside the United States and Canada, has announced that KEYTRUDA, Merck’s anti-PD-1 therapy,……
Keytruda nabs key lung cancer nod in China fiercepharma
April 02, 2019
Less than a year after securing its first Chinese approval, in previously treated metastatic melanoma patients……
New lung cancer indication for Keytruda combo OK’d in EU pharmatimes
March 19, 2019
MSD’s anti-PD-1 therapy Keytruda has been approved for use in combination with carboplatin and either paclitaxel or nab-paclitaxel for first-line treatment of adults with metastatic squamous non-small cell lung cancer (NSCLC).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 16 17 Next page